Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy

Cancer

Volumn 106, Issue 1, 2006, Pages 42-50

  Adepoju, Linda J ^a   Symmans, W Fraser ^a   Babiera, Gildy V ^a   Singletary, S Eva ^a   Arun, Banu ^a   Sneige, Nour ^a   Pusztai, Lajos ^a   Buchholz, Thomas A ^a   Sahin, Aysegul ^a   Hunt, Kelly K ^a   Meric Bernstam, Funda ^a   Ross, Merrick I ^a   Ames, Frederick C ^a   Kuerer, Henry M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast carcinoma prevention; Breast conservation; Ductal carcinoma in situ; Surgery; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST DUCT; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CARCINOMA IN SITU; CELL PROLIFERATION; FEMALE; HIGH RISK PATIENT; HUMAN; IPSILATERAL BREAST CARCINOMA RECURRENCE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; PRIORITY JOURNAL; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PRECANCEROUS CONDITIONS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT;

EID: 29744456025     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21571     Document Type: Article

References (42)

1. Fentiman IS. The dilemma of in situ carcinoma of the breast. Int J Clin Pract. 2001;55:680-683.
2. American Cancer Society. Cancer facts and figures 2005 [monograph online; accessed Februrary 4, 2005].
3. Solin LJ, Recht A, Fourquet A, et al. Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer. 1991;68:2337-2344.
4. Ottesen GL, Graversen HP, Blichert-Toft M, Christensen J, Andersen JA. Carcinoma in situ of the female breast. 10 year follow up results of a prospective nationwide study. Breast Cancer Res Treat. 2000;67:197-210.
5. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes J. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study. Pathology. 2004;36:221-229.
6. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. Cancer. 1985;55:2698-2708.
7. Bodian CA, Perzin KH, Lattes R, Hoffman P, Abernathy TG. Prognostic significance of benign proliferative breast disease. Cancer. 1993;71:3896-3907.
8. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-944.
9. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk and associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258-1265.
10. Shaaban AM, Sloane JP, West CR, et al. Histopathologic types of benign breast lesions and the risk of breast cancer. Am J Surg Pathol. 2002;26:421-430.
11. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297-301.
12. Page DL, Anderson TJ. Diagnostic histopathology of the breast. London: Churchill Livingstone, 1987.
13. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy predictors of significant histologic findings. Cancer. 2004;101:1977-1986.
14. Fisher B, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast project (NSABP) eight-year update of protocol B-17. Cancer. 1999;86:429-438.
15. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19:2263-2271.
16. Fisher B, Constantine J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581-1586.
17. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355:528-533.
18. Solin LJ, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Cancer. 1993;71:2532-2542.
19. Roka S, Rudas M, Taucher S, et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol. 2004;30:243-247.
20. Jhingran A, Soo Kim J, Buchholz TA, et al. Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: the University of Texas M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 2002;54:804-809.
21. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95:1692-1702.
22. Haffty BG, Moran M. Lobular carcinoma in situ as a component of breast cancer: the long term outcome in patients treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 1998;40:353-358.
23. Carolin KA, Tekyi-Mensah S, Pass HA. Lobular carcinoma in situ and invasive cancer: the contralateral breast controversy. Breast J. 2002;8:263-268.
24. Abner AL, Connolly JL, Recht A, et al. The relation between the presence and extent of tabular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer. 2000;88:1072-1077.
25. Sasson AR, Fowble B, Hanlon AL, et al. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer. 2001;91:1862-1869.
26. Fowble B, Hanlon A, Patchefsky A, et al. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. Int J Radiat Oncol Biol Phys. 1998;42:105-115.
27. Fisher B, Constantine J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581-1586.
28. Arpino G, Allred DC, Mohshin SK, Weiss HL, Cornrow D, Elledge RM. Lobular neoplasia on core-needle biopsy-clinical significance. Cancer. 2004;101:242-250.
29. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125-129.
30. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
31. Morrow M. Precancerous breast lesions: implications for breast cancer prevention trials. Int J Radiat Oncol Biol Phys. 1992;23:1071-1078.
32. Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol. 2001;70:303-316.
33. Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I. Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev. 1998;22:313-318.
34. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast: histologic categorization and its relationship to ploidy and immunohistochemical expression of receptors, p53, and c-erbB-2 protein. Cancer. 1995;75:2123-2131.
35. Lebeau A, Unholzer A, Amann G, et al. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2003;79:187-198.
36. Berardo MD, Hilsenbeck SG, Allred DC. Histologic grading of non-invasive breast cancer and its relationship to biological features (abstract). Lab Invest. 1996;74:15A.
37. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer. 1992;69:1174-1181.
38. Fisher ER, Constantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Cancer. 1996;78:1403-1416.
39. Shoker BS, Jarvis C, Sibson RD, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol. 1999;188:237-244.
40. Gillett CE, Lee AHS, Millis RR, Barnes DM. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol. 1998;184:396-400.
41. Fisher B, Constantine JP, Wickerman LD, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371-1388.
42. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 1999;353:1993-2000.